

DEPARTMENT OF HEALTH

MEDICINES CONTROL AGENCY

Market Towers, 1 Nine Elms Lane, London SW8 5NQ. Telephone 071-273 0422, or 0425

Product Licences Authorised

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
0006/0266	Lilly Industries Limited, t/a Eli Lilly and Company Limited; Dista Products Limited; Greenfield Pharmaceuticals	Lorabid Capsules 200 mg	Loracarbef (Monohydrate) HSE 210.3 mg Equivalent to Loracarbef 200.0 mg	Treatment of the following infections, in both adults and children over 6 months of age, when caused by susceptible strains of the designated organisms. Otitis media caused by streptococcus pneumoniae, haemophilus influenzae (including beta-lactamase producing strains), moraxella catarrhalis (including beta-lactamase producing strains), streptococcus pyogenes (group A beta-haemolytic streptococci) and staphylococcus SP. Acute bronchitis and acute exacerbations of chronic bronchitis caused by S pneumoniae, H influenzae (including beta-lactamase producing strains), haemophilus parainfluenzae, M. Catarrhalis (including beta-lactamase producing strains), klebsiella pneumoniae, neisseria meningitidis, staphylococcus aureus, S. Pyogenes (group A beta-haemolytic streptococci) and viridans streptococci. Pneumonia caused by S pneumoniae, H influenzae (including beta-lactamase producing strains), H parainfluenzae and M catarrhalis (including beta-lactamase producing strains). Sinusitis caused by S pneumoniae, H influenzae (including beta-lactamase producing strains), M catarrhalis (including beta-lactamase producing strains) and S pyogenes (group A beta-haemolytic streptococci). Pharyngitis and tonsillitis caused by S pyogenes (group A beta-haemolytic streptococci). Loracarbef is generally effective in the eradication of streptococci from the oropharynx. Uncomplicated lower urinary tract infections, including cystitis and asymptomatic bacteriuria caused by escherichia coli, K pneumoniae, proteus mirabilis and staphylococcus saprophyticus. Uncomplicated pyelonephritis caused by E coli and P mirabilis. Skin and skin structure infections caused by S pyogenes (group A beta-haemolytic streptococci), S aureus and staphylococcus epidermidis. Bacteriological studies to determine the causative organism and its susceptibility to Loracarbef should be performed. Therapy may be started while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. Loracarbef is inactive against most strains of Acinetobacter, Enterobacter, Morganella morganii, Proteus vulgaris, Providencia, Pseudomonas and Serratia. Most anaerobes are resistant to Loracarbef, as are methicillin-resistant staphylococci. POM (See PL/0006/0266).	12th April 1994
0006/0267	Lilly Industries Limited, t/a Eli Lilly and Company Limited; Dista Products Limited; Greenfield Pharmaceuticals	Lorabid Capsules 400 mg	Loracarbef (Monohydrate) HSE 420.6 mg Equivalent to Loracarbef 400.0 mg	(See PL/0006/0266).	12th April 1994
0006/0268	Lilly Industries Limited, t/a Eli Lilly and Company Limited; Dista products Limited; Greenfield Pharmaceuticals	Lorabid Ganules for Suspension 100 mg/5 ml	Loracarbef (Monohydrate) HSE 150.15 mg Equivalent to Loracarbef 100.0 mg	(See PL/0006/0266).	11th April 1994
0006/0269	Lilly Industries Limited, t/a Eli Lilly and Company Limited; Dista Products Limited; Greenfield Pharmaceuticals	Lorabid Granules for Suspension 200 mg/5 ml	Loracarbef (Monohydrate) HSE 210.3 mg equivalent to Loracarbef 200.0	(See PL/0006/0266).	11th April 1994
0006/0293	Lilly Industries Limited t/a Eli Lilly and Company Limited, Dista Products Limited, Greenfield Pharmaceuticals	Nu-Seals 75	Acetylsalicylic Acid EP 75.0 mg	Wherever high or prolonged dosage of aspirin is required. The special coating resists dissolution in gastric juice, but will dissolve readily in the relatively less acid environment of the duodenum. Owing to the delay that the coating imposes on the release of the active ingredient, unsuitable for short-term relief of pain. PM	21st April 1994
0014/0456	The Boots Company Plc	Boots Dual Action Athlete's Foot Powder	Tolnaftate BP 1.0% w/w Chlorhexidine Hydrochloride BP 0.25% w/w	For the adjunctive treatment and prevention of athlete's foot (Tinea Pedis). It may also be helpful in conditions where tenderness and sweating cause skin irritation. It is also effective in other conditions, such as dhobie itch (Tinea	5th April 1994